Biotechnology · Nasdaq: REGN
Regeneron earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 29 Jan 2027
Latest: Q3 2026
Regeneron expanded its Sanofi alliance to add four Regeneron-invented, long-acting next-generation immunology antibodies meant to build on Dupixent, backed by a $1.0 billion up-front payment.
Regeneron's three core brands, Dupixent, EYLEA HD and Libtayo, each posted record quarterly sales on broad demand. EYLEA HD gained ground as retinal specialists adopted it after label enhancements, while older EYLEA lost volume to competition and the switch to EYLEA HD. Libtayo grew on an adjuvant skin cancer approval, and a shorter-interval dosing schedule won a positive European opinion. The FDA approved Pasatru for FOP, and a U.S. government agreement will supply Inmazeb for Ebola preparedness.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $3.8B * |
| Q1 2025 | $3.0B |
| Q2 2025 | $3.7B |
| Q3 2025 | $3.8B |
| Q4 2025 | $3.9B * |
| Q1 2026 | $3.6B |
| Q2 2026 | $4.3B |
| Q3 2026 | $5.1B |
Data
| Q1 2025 | $7.27 |
| Q2 2025 | $12.81 |
| Q3 2025 | $13.62 |
| Q1 2026 | $6.75 |
| Q2 2026 | $12.23 |
| Q3 2026 | $18.45 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 26.1% |
| Q1 2025 | 19.5% |
| Q2 2025 | 29.4% |
| Q3 2025 | 27.3% |
| Q4 2025 | 22.7% |
| Q1 2026 | 17.8% |
| Q2 2026 | 30.1% |
| Q3 2026 | 40.0% |
Data
| Q4 2024 | $1.1B |
| Q1 2025 | $815.8M |
| Q2 2025 | $925.4M |
| Q3 2025 | $1.4B |
| Q4 2025 | $922.0M |
| Q1 2026 | $848.3M |
| Q2 2026 | $572.8M |
| Q3 2026 | $1.5B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8Bd | $3.0B | $3.7B | $3.8B | $3.9Bd | $3.6B | $4.3B | $5.1B |
| Operating income | $990.2Md | $591.7M | $1.1B | $1.0B | $879.9Md | $642.9M | $1.3B | $2.0B |
| Operating margin | 26.1% | 19.5% | 29.4% | 27.3% | 22.7% | 17.8% | 30.1% | 40.0% |
| Net income | $917.7Md | $808.7M | $1.4B | $1.5B | $844.6Md | $727.2M | $1.3B | $1.9B |
| Diluted EPS | — | $7.27 | $12.81 | $13.62 | — | $6.75 | $12.23 | $18.45 |
| Operating cash flow | $1.3Bd | $1.0B | $1.1Bd | $1.6Bd | $1.2Bd | $1.1B | $813.0Md | $1.8Bd |
| Capital expenditure | $199.6Md | $229.3M | $219.0Md | $201.4Md | $248.7Md | $230.6M | $240.2Md | $300.2Md |
| Free cash flow | $1.1B | $815.8M | $925.4M | $1.4B | $922.0M | $848.3M | $572.8M | $1.5B |
| R&D expense | $1.4Bd | $1.3B | $1.4B | $1.5B | $1.6Bd | $1.5B | $1.6B | $1.8B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 30 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 30 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 29 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 4 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 28 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 29 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 5 Feb 202510-K for the period ended 31 Dec 2024SEC ↗